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Due to interesting therapeutic properties of 177Lu and tumor avidity of tetraphenyl porphyrins (TPPs), 
177Lu-tetraphenyl porphyrin was developed as a possible therapeutic compound. 177Lu of 2.6-3 GBq/mg  
specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 
4 × 1013 n.cm-2.s-1. Tetraphenyl porphyrin was synthetized and labeled with 177Lu. Radiochemical purity of 
the complex was studied using Instant thin layer chromatography (ITLC) method. Stability of the complex 
was checked in final formulation and human serum for 48 h. The biodistribution of the labeled compound 
in vital organs of wild-type rats was studied up to 7 d. The absorbed dose of each human organ was 
calculated by medical internal radiation dose (MIRD) method. A detailed comparative pharmacokinetic 
study was performed for 177Lu cation and [177Lu]-TPP. The complex was prepared with a radiochemical 
purity: >97±1% and specific activity: 970-1000 MBq/mmol. Biodistribution data and dosimetric results 
showed that all tissues receive approximately an insignificant absorbed dose due to rapid excretion of 
the complex through the urinary tract. [177Lu]-TPP can be an interesting tumor targeting agent due to low 
liver uptake and very low absorbed dose of approximately 0.036 to the total body of human.
Uniterms: Radiopharmaceuticals/internal dosimetry. Lutetium-177. 177Lu-tetraphenyl porphyrin/
biodistribution. Porphyrins/biodistribution. Medical internal radiation dose. MIRD.
Devido às propriedades interessantes do 177Lu e da avidez tumoral das tetrafenil porfirinas (TPP), 
desenvolveu-se a 177Lu-tetrafenil porfirina como composto terapêutico potencial. 177Lu de atividade 
específica de 2,6-3 GBq/mg foi obtido por irradiação de amostra de Lu2O3 com fluxo térmico de nêutrons 
de 4 × 1013 n.cm-2.s-1 . Sintetizou-se a tetrafenil porfirina e marcou-se com 177Lu. A pureza radioquímica 
do complexo foi estudada usando método de Cromatografia Instantânea de Camada Delgada ( ITLC). A 
estabilidade do complexo foi checada na formulação final e no ser humano por 48 h. A biodistribuição 
do composto marcado em órgãos vitais de ratos do tipo selvagem foi estudada por mais de 7 dias. A 
dose absorvida para cada órgão humano foi calculada pelo método da Dose Médica de Radiação Interna 
(MIRD). Estudo farmacocinético comparativo detalhado foi efetuado para o cátion 177Lu e para o [177Lu]-
TPP. O complexo foi preparado com pureza radioquímica >97±1% e atividade específica de 970-1000 
MBq/mmol. Os dados de biodistribuição e os resultados dosimétricos mostraram que todos os tecidos 
receberam uma dose absorvida aproximadamente insignificante devido à rápida excreção do complexo 
pelo trato urinário. O [177Lu]-TPP pode ser um agente interessante de direcionamento do tumor devido 
à baixa captação pelo fígado e pela dose bem baixa absorvida, de, aproximadamente, 0,036 do corpo 
humano total.
Unitermos: Radiofármacos/dosimetria interna. Lutécio-177. 177Lu-tetrafenil porfirina/biodistribuição. 
Porfirinas/biodistribuição. Dose Médica de Radiação Interna.
S. Zolghadri, H. Yousefnia, A. R. Jalilian, Y. Fazaeli340
INTRODUCTION
Nowadays, radiopharmaceuticals are widely 
used for diagnostic and therapeutic purposes. An 
ideal radiopharmaceutical should lead to substantially 
greater accumulation rate in the target organ while the 
accumulation in other organ should be as low as possible. 
Therefore, scientists have paid attention to new ligands 
to differentiate between malignant and normal cells 
(Sanderson et al., 1972).
Porphyrin is a heterocyclic macrocycle derived from 
four pyrrole-like subunits that plays an important role in 
biological transfer systems. Various porphyrin complexes 
have shown interesting tumor-avid activity in vitro and in 
vivo (Subbarayan et al., 2001; Das et al., 2008; Bonnett, 
1995; Jori, 1996).
Radiolabeled porphyrins have been developed for 
the therapeutic purposes such as, 109Pd-protoporphyrins 
(Fawwaz et al., 1974), 109Pd-porphyrins (Fawwaz, 
Hemphill, Winchell, 1971), 109Pd-derivitized porphyrins 
(Chakraborty et al., 2007), 188Re-porphyrins (Jia, Deng, 
Pu, 2007; Sarma et al., 2010), 123I-Porphyrins (Jae Hak 
et al., 2007). Various radiolabeled porphyrin complexes 
such as 57Co-porphyrins (Hambright et al., 1976), 
99mTc-porphyrin (Murugesan et al., 2001; Wang, Lin, Lin, 
2010), and 111In-porphyrin (Fazaeli et al., 2012) have also 
been introduced for imaging.
While the masive accumulation of 109Pd-porphyrins 
was indicated in fibrosarcoma tumours (Chakraborty et 
al., 2007), I-123-labeled porphyrin demonstrated high 
focal accumulation in the B16-F10 melanoma tumor (Jae 
Hak et al., 2007). (188)Re-labeled 5,10,15,20-tetrakis[3,4-
bis(carboxymethyleneoxy)phenyl]porphyrin has also 
shown specific affinity toward the fibrosarcoma and 
thymic lymphoma tumors in mice (Sarma et al., 2010).
Accumulation of the radiolabeled prophyrins 
in tumour is dependent on various parameters such 
as porphyrin structure, choice of radioisotope, pH, 
the presence of inflammation and many other factors. 
However, the balance between hydrophilicity and 
lipophilicity is also recognized as an important factor 
in tumour accumulation. Whereas, lipophilicity of the 
agent plays an important role in tumor accumulation, 
hydrophilicity is a significant key in the clearance of the 
agent from the non-target organs. Therefore, a balance 
between these two properties is necessary for developing 
a suitable agent and for contributing to the challenge in 
designing suitable derivatives of porphyrin (Das et al., 
2010).
177Lu decays with a half life of 6.73 d by emission 
b-particles with maximum energy of 497 keV (78.6%) 
and g-photons of 112 keV (6.4%) and 208 keV (11%) 
to stable 177Hf (TOI, 1993). Due to these good physical 
characteristics as well as the feasibility of large-scale 
production in adequate specific activity and radionuclidic 
purity using a moderate flux reactor, 177Lu has been 
considered as a promising radionuclide for developing 
therapeutic radiopharmaceuticals due to its suitable half-
life.
177Lu-radiopharmaceuticals have been developed and 
used in the therapy of various diseases and malignancies, 
such as somatostatin receptor radiotherapy (Bodei et 
al., 2009), radioimmunotherapy (Michel et al., 2005), 
bone palliation therapy (Chakraborty et al., 2008a) 
and radiosynovectomy (Chakraborty et al., 2006; 
Chakraborty et al., 2008b). 177Lu-5,10,15,20-tetrakis[4-
carboxymethyleneoxyphenyl] porphyrin have recently 
been developed and have shown active tumor uptake in 
mice bearing fibrosarcoma tumors (Das et al., 2010).
According to the interesting pharmacological 
properties of porphyrins such as solubility in serum, 
rapid wash-out, tumor avidity and feasible complexation 
with various bi/tri-valent metals (Falk, 1975), the idea 
of developing a possible tumor targeting agent by 
incorporating 177Lu into a suitable porphyrin ligand, i.e. 
TPPH2 was investigated (Figure 1).
As for the amount of energy uptake in any organs 
by ionizing radiation, the absorbed dose, plays an 
important role in evaluating the risks associated with 
the administration of radiopharmaceuticals and thus the 
maximum amount of activity that should be undertaken 
(Stabin et al., 1999). In nuclear medicine, the most 
commonly used method for calculation of the internal 
dose estimates is the one developed by the medical 
internal radiation dose (MIRD) committee (Stabin, 1996) 
FIGURE 1 - Structure of TPPH2.
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summarized in MIRD primer (Loevinger, Budinger, 
Watson, 1988).
In this work, we endeavour to report, synthesis, 
radiolabeling, quality control and biodistribution studies 
of 177Lu-TPP in wild-type rats. The time/decay diagrams 
for the labeled compound in vital organs were plotted 
compared to lutetium cation. Also the partition coefficient 
of the complex was calculated and the absorbed dose to 
each organ of human was evaluated by biodistribution 
studies in rats by MIRD method.
MATERIAL AND METHODS
177Lu was produced at Tehran Research Reactor. 
Chemicals were purchased from the Aldrich Chemical 
Co. (Gemany). NMR spectra were obtained on a FT-80 
Varian instrument (80 MHz) with tetramethylsilane as an 
internal standard. Infrared spectrum was measured on a 
Perkin-Elmer 781 spectrometer by means of a KBr disc. 
Mass spectrum was recorded by a Finnigan Mat TSQ-70 
Spectrometer. Thin layer chromatography (TLC) for cold 
compounds was performed on polymer-backed silica gel 
(F 1500/LS 254, 20 × 20 cm, TLC Ready Foil, Schleicher 
& Schuell®, Germany). Normal saline and sodium 
acetate used for labeling were of high purity and had 
been filtered through 0.22 mm Cativex filters. Instant thin 
layer chromatography (ITLC) was performed by counting 
Whatman No. 2 papers using a thin layer chromatography 
scanner, Bioscan AR2000, Bioscan Europe Ltd. (France). 
Biodistribution data were obtained by counting normal 
saline washed tissues after weighing on a Canberra­TM 
high purity germanium (HPGe) detector (model GC1020-
7500SL). Radionuclidic purity was checked with the 
same detector. For activity measurement of the samples 
a CRC Capintech Radiometer (NJ, USA) was utilized. 
All calculations as well as tissue count were based on the 
112 keV peak of 177Lu. Animal studies were performed in 
accordance with the United Kingdom Biological Council’s 
Guidelines on the Use of Living Animals in Scientific 
Investigations, 2nd ed.
Production and quality control of 177LuCl3 solution
177Lu was produced by irradiation of natural Lu2O3 
target (1 mg) at a thermal neutron flux of approximately 
4 × 1013 n/cm2.s for 5 days at Tehran Research Reactor 
(TRR) according to the reported procedures (Yousefnia et 
al., 2011). The irradiated target was dissolved in 200 µL 
of 1.0 M HCl, to prepare 177LuCl3 and diluted to the 
appropriate volume with ultra pure water, to produce a 
stock solution of final volume of 5 mL with approximately 
2.8 GBq. The mixture was filtered through a 0.22 µm 
biological filter and sent for use in the radiolableing stage 
in the process. For radionuclidic purity determination, 
the sample was checked by gamma-ray spectroscopy on 
an HPGe detector for 5 h based on two major photons of 
177Lu (6.4% of 0.112 MeV and 11% of 0.208 MeV). The 
radiochemical purity of the 177LuCl3 was checked using 2 
solvent systems for ITLC (A: 10 mM DTPA pH.4 and B: 
ammonium acetate 10%:methanol (1:1)).
Preparation of Tetraphenyl Porphyrin (TPPH2)
This compound was prepared according to the 
reported method using freshly distilled benzaldehyde, 
pyrrole and propionic acid followed by oxidation 
(Adler et al., 1967). Yield; 20%, m.p.> 248-250 °C. 1H 
NMR (CDCl3) d (ppm) –2.8 (2 H, NH), 7.71-7.82 (12 
H), 8.14-8.27 (8 H), 8.85 (8 H). 13C-NMR (CDCl3) 
d  (ppm) 120.20 (C), 126.74 (CH), 127.76 (CH), 
131.16 (CH), 134.62 (CH), 142.22 (C), 145.6 (C).UV 
(toluene) λmax (ε) = 418 nm (413200), 514 (19060), 549 
(8080), 594 (5380), 648 (3870). IR (KBr) 3320, 3055, 
3025, 1595.
Preparation of [177Lu]-TPP
0.2 ml of 177LuCl3 with 111 MBq radioactivity was 
transferred to a 5 mL-borosilicate vial and heated to 
dryness by using a flow of N2 gas at 50-60 °C, followed by 
the addition of fifty microliters of TPP in absolute ethanol 
(1 mg/mL ≈­81 nmoles) and 450 microliters of acetate 
buffer pH 5 (0.1 M). The mixture vortexed at 25 °C for 
4 h. The final solution was then passed through a 0.22 mm 
filter and the radiochemical purity was checked by ITLC. 
For this purpose, 5 mL of the final solution was spotted on 
a chromatography Whatman No. 2 paper, and developed 
in two mobile phase mixtures, A: water:acetonitrile (3:1) 
and B: water:acetonitrile (1:3).
Determination of partition coefficient
Partition coefficient (log P) of [177Lu]-TPP was 
calculated. A mixture of 1 mLof 1-octanol and 1 mL 
of isotonic acetate-buffered saline (pH 7) containing 
approximately 3.7 MBq of the radiolabeled complex 
at 37 °C was vortexed 1 min and left 5 min. Following 
centrifugation at >1200 g for 5 min, the octanol and 
aqueous phases were sampled and counted in an automatic 
well-type counter. A 500 μL sample of the octanol phase 
from this experiment was shaken again thrice with fresh 
buffer samples. The reported log P values are the average 
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of the second and third extractions from three to four 
independent measurements.
Stability tests
The stability of the complex was checked according 
to the conventional ITLC method. A sample of [177Lu]-TPP 
(37 MBq) was kept at room temperature for 2 days while 
being checked by ITLC at time intervals in order to check 
stability in final product using above chromatography 
system. For serum stability studies, to 36.1 MBq of [177Lu]-
TPP was added 500 mL of freshly collected human serum 
and the resulting mixture was incubated at 37 °C for 5 h; 
Aliquots (5 mL) were analyzed by ITLC.
Biodistribution in wild-type rats
 The distribution of 177Lucl3 and the radiolabeled 
complex among tissues were determined for wild-type 
rats. 50–100 µL of 177Lu-TPP or 177LuCl3 solutions with 
1.85 MBq radioactivity were injected intravenously 
via their tail veins. The total amount of radioactivity 
injected into each rat was measured by counting the 1 
mL syringe before and after injection in a dose calibrator 
with fixed geometry. The animals were sacrificed by CO2 
asphyxiation at selected times after injection (2, 4, 24, 
48, 120 and 168 h). The tissues (blood, heart, lung, brain, 
intestine, feces, skin, stomach, kidneys, liver, muscle and 
bone) were weighed and rinsed with normal saline and 
their specific activities were determined with an HPGe 
detector equipped with a sample holder device as percent 
of injected dose per gram of tissues.
Dosimetric studies
The absorbed dose of each human organ was 
calculated by MIRD method based on biodistribution data 
in wild-type rats. The accumulated activity in animals 
was extrapolated to the accumulated activity in humans 
by the proposed method of Sparks et al. (eq. 1) (Sparks, 
Aydogan, 1996).
A human organ=A animal organ human human
animal animal
OrganMass
OrganMass
/ BodyMass
/ BodyMass  (1)
where Ã is the accumulated activity in the source organs 
and can be calculated by the equation 2.
 
1t
Ã = A (t) dt
∞∫   (2)
It should be noticed that A (t) is the activity of each 
organ at time t.
The accumulated source activity for each organ of 
animals was calculated by plotting the percentage-injected 
dose versus time for each organ and computing the area 
under the curves. For this purpose, the data points which 
represent the percentage-injected dose were created. 
The curves were extrapolated to infinity by fitting the 
tail of each curve to a monoexponential curve with the 
exponential coefficient equal to physical decay constant 
of 177Lu. Then the area under the curve was calculated. In 
order to extrapolate this accumulated activity to human, 
the mean weights of each organ for standard human were 
used (Table I).
The radiation absorbed dose was calculated by 
MIRD formulation (Henrichs, Kaul, Roedler, 1982):
 k h k h
h
D(r ) A S(r r )= × ←∑   (3)
where D(rk) is the absorbed dose of the target 
organ, and S(rk ←––– rh) called S factor which is defined 
as the mean absorbed dose to the target region rk per unit 
accumulated activity in the source region rh. S factor 
represents the physical decay characteristics of the 
radionuclide, the range of the emitted radiations, and the 
organ size and configuration (Bevelacqua, 2005) expressed 
in mGy/MBq.s. The S factors have been taken from the 
OLINDA software (OLINDA, 2007).
RESULTS AND DISCUSSION
Radionuclide production
The radionuclide was prepared in a research reactor 
according to the regular methods with a range of specific 
TABLE I - The mean weights of organs for human with standard 
weight (ICRP 89, 2001)
Organ Weight (g)
Bone 5500
Heart 330
Stomach 150
Kidneys 310
Small intestine 650
Spleen 150
Muscle 29000
Liver 1800
Lung 500
Total body 73000
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activity 2.6-3 GBq/mg for radiolabeling use. The obtained 
radionuclidic purity was 99.98% (Figure 2). Furthermore, 
half-life of the 177Lu was also studied by counting the 
sample at different time intervals. The decay scheme for 
the radionuclide is shown in Figure 3.
The radioisotope was dissolved in acidic media as a 
starting sample and was further diluted and evaporated for 
obtaining the desired pH and volume followed by sterile 
filtering. The radiochemical purity of the 177Lu solution 
was checked in two solvent systems: in 10 mM DTPA, free 
Lu3+ cation as a complex in more lipophilic LuDTPA form 
migrates to higher Rf, while small radioactive fraction 
remains in its origin which could be related to other Lu 
ionic species, not forming LuDTPA complex, such as 
LuCl4
-, etc. and/or colloids.
FIGURE 2 - Gamma-ray spectrum for 177LuCl3 solution used 
in this study. FIGURE 3- Decay scheme for 177Lu used in this study.
FIGURE 4 - ITLC chromatograms of 177LuCl3 solution in DTPA solution (pH. 4) (left) and 10% ammonium acetate:methanol (1:1) 
solution (right) using Whatman No. 2.
On the other hand, 10% ammonium acetate:methanol 
mixture was also used for the determination of 
radiochemical purity. In this solvent system, the fast 
eluting species were possibly Lu-177 cations, other than 
Lu3+ and the remaining fraction at Rf.0 was a possible 
mixture of Lu3+ and/or colloids. The difference in values 
of impurity in two solvent systems is possibly due to the 
presence of colloidal impurity in the sample (Figure 4).
Preparation of [177Lu]- TPP
The synthetic scheme for radiolabeling of TPP 
with 177LuCl3 is demonstrated in Figure 5. Because of 
the engagement of NH polar functional groups in its 
structure, labeling of TPPH2 with lutetium cation affects 
its chromatographic properties and the final complex is 
more lipophilic. Two different chromatographic systems 
were used. Using water/acetonitrile (1:3) mixture, free 
lutetium remains in its origin of the paper as a single peak, 
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while the radiolabeled compound migrates to higher Rf. 
Using a more polar mobile phase, acetonitrile:water (1:3), 
free lutetium cation migrated to a higher Rf, while the 
radiolabeled compound remained at the origin (Figure 6).
Partition coefficient
As expected, the lipophilicity of the [177Lu]-TPP 
compound is rather high. The measured octanol/water 
partition coefficient, P, for the complex was found to depend 
on the pH of the solution. At the pH 7, the log P was 1.63.
Stability
The stability of [177Lu]-TPP prepared complex 
at room temperature was checked up to 48 hours. The 
radiochemical purity of the complex remained at 98% for 
2 days. Also the stability of the complex was determined 
at 37 °C for 48 h and the data were almost consistent with 
the final solution stability.
Biodistribution studies of 177Lucl3 and 177Lu-TPP in 
wild-type rats
The animals were sacrificed by CO2 asphyxiation 
at selected times after injection (2, 4, 24, 48 and 168 h). 
The biodistribution data show that the liver uptake of 
FIGURE 5 - Synthetic scheme for radiolabeling of TPP with 
177LuCl3.
FIGURE 6 - ITLC chromatograms of 177LuCl3 and 177Lu-TTP on Whatman No. 2 paper using water:acetonitrile (1:3) [up (a & b)] 
and acetonitrile:water (1:3) [down (c & d)] mixtures.
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FIGURE 7 - Percentage of injected dose per gram (ID/g%) of 177LuCl3 in wild-type rat tissues at 2, 4, 24, 48 and 168 h post injection 
(ID/g%: percentage of the injected dose per gram of tissue calculated based on the area under curve of 112 keV peak in gamma 
spectrum) (n=5).
FIGURE 8 - Biodistribution of [177Lu]-TPP (1.85 MBq) in wild type rats 2, 24, 120 and 168 h after iv injection via tail vein (ID/g%: 
percentage of injected dose per gram of tissue calculated based on the area under curve of 112 keV peak in gamma spectrum) (n=5)
the cation is comparable to many other radio-metals 
mimicking ferric cation accumulation; about 3% of the 
activity accumulates in the liver after 48 h. Binding of 
177Lu by transferrin and transport to the liver appears to 
be the route of accumulation (Figure 7).
As it can be seen from Figure 5, the blood content is 
low at all time intervals, which shows the rapid removal 
of activity in the circulation. The lung, muscle and also 
skin do not demonstrate significant uptake while it is in 
accordance with other cations accumulation. A 5% bone 
uptake is observed for the cation at 168 h. The spleen also 
has uptake (1%) possibly related to reticuloendothelial 
uptake. The kidney plays an important role in 177Lu cation 
excretion especially after 24 h (1%). Biodistribution of 
177Lu-TPP in different organs of wild-type rats is shown 
in Figure 8.
Comparison of vital organs uptake for 177Lu-TPP and 
177LuCl3 demonstrates kinetic pattern difference for both 
species. 177Lu cation is accumulated in the liver within the 
first 24 h post injection slightly, while 177Lu-TPP second 
major excretion route is through the liver and slow uptake 
of less than 1% is observed in 168 h for the radiolabeled 
compound (Figure 9).
Intestinal activity increases in 177Lu3+ after 7 days 
as a consequence of the liver excretion through GI tract, 
however, in case of Lu porphyrin, the amount of activity 
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The accumulation of the tracer in other tumor models is 
under investigation due to the low liver uptake and rapid 
excertion through the urinary tract. Biodistribution data 
and dosimetric results showed that all tissues receive 
virtually insignificant absorbed dose due to rapid excretion 
of the complex through the urinary tract. [177Lu]-TPP can 
be an interesting tumor targeting agent due to the low liver 
uptake and very low absorbed dose of approximately 0.036 
mSv/MBq to the total body of human.
TABLE Π -  Absorbed dose in each organ of human after injection 
of 177Lu-TPP
Organ
Absorbed 
Dose 
(mSv/MBq)
Organ
Absorbed 
Dose 
(mSv/MBq)
Adrenals 0.005 Ovaries 0.003
Brain 0.001 Pancreas 0.005
Breasts 0.001 Red Mar. 0.069
GB Cont. 0.006 Cort Bone Sur. 0.081
LLI Cont. 0.101 Trab. Bone 
Sur.
0.105
SI Cont. 0.003 Cort Bone Vol. 0.039
Stom. Cont. 0.036 Trab. Bone 
Vol.
0.099
ULI Cont. 0.003 Spleen 0.149
Heart Cont. 0.007 Testes 0.001
Heart Wall 0.015 Thymus 0.002
Kidneys 0.313 Thyroid 0.002
Liver 0.233 UB Cont 0.002
Lungs 0.089 Uterus 0.002
Muscle 0.033 Tot. Body 0.036
FIGURE 10 - The clearance curves from each organ of the rats.
FIGURE 9 - Comparative organ uptake of 177LuCl3 and 177Lu-
TPP in wild-type rats.
decreases due to the low liver uptake compared with 
urinary excretion. As shown earlier, 177Lu cation is slightly 
absorbed in the skeletal system (5%) while the labeled 
compound almost shows no uptake in the bone.
Since the urinary tract is a major route of excretion 
of the porphyrins, the amount of the kidney activity is 
maximum for the labeled compound especially after 24 h, 
however in 7days major urinary excretion is observed 
in free cation. The circulation wash-out for the labeled 
compound is observed while a lesser amount of activity 
in blood is observed for free Lu cation.
Dosimetric studies
Dosimetric evaluation in human organs was made by 
MIRD method based on biodistribution in rat organs. The 
clearance curves from each organ of the rats are shown in 
Figure 10. The absorbed dose in each organ of human after 
injection of 177Lu-TPP is given in Table Π.
CONCLUSION
Total labeling and formulation of [177Lu]-TPP took 
about 4 h (radiochemical purity: >97 ± 1% ITLC, specific 
activity, 970-1000 MBq/mmol). The complex was stable 
in final formulation and human serum at least for 24 h. The 
biodistribution of the labeled compound in vital organs 
of wild-type rats was studied up to 7 days post injection. 
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